Clinical trial · Observational
Cross-cultural Adaptation and Validation of the P-CIN for Chinese Pediatric Oncology Patients
Cross-cultural Adaptation and Validation of the Pediatric Chemotherapy-induced Neuropathy (P-CIN) for Chinese Pediatric Oncology Patients: A Multi-center Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study was to conduct a cross-cultural adaptation of the P-CIN into the Chinese context, assess its psychometric properties, and determine the cut-off value of CIPN among Chinese pediatric oncology patients. Participants provided demographic and clinical characteristics, and complete the translated P-CIN, Wong-baker FACES Pain Rating scale for pain, and Chinese version of the Pediatric Quality of Life Inventory (PedsQL) Cancer Module for quality of life.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pediatric Cancer | Childhood Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Questionnaire
- description
- Participants completed the translated P-CIN, Wong-baker FACES Pain Rating scale for pain, and Chinese version of the Pediatric Quality of Life Inventory (PedsQL) Cancer Module for quality of life.
Primary outcomes (1)
- measure
- Pediatric chemotherapy-induced peripheral neuropathy (P-CIN) scale
- timeFrame
- Baseline
- description
- For measuring participants' peripheral neuropathy induced by chemotherapy. The total score ranges from 0 to 65 with higher scores indicating more severe chemotherpay induced peripheral neuropathy.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Years
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * (1) 6 to 18 years of age * (2) were diagnosed with cancer * (3) had received or were currently receiving neurotoxic chemotherapy drugs (e.g., Vincristine, Cisplatin, Carboplatin, Oxaliplatin, Paclitaxel, Docetaxel, Ixabepilone, Bortezomib, Thalidomide) * (4) were able to communicate, read, and write in Chinese without significant hearing and vision problems to ensure they understood the P-CIN. Exclusion Criteria: * (1) had a diagnosis of cancer in the central nervous system (CNS) cancer, cancer relapse or secondary cancer * (2) in the terminal stage * (3) planned to receive multiple cancer treatment (e.g., radiotherapy and immunotherapy) * (4) suffered from other neuromuscular diseases (e.g., traumatic brain injury and cerebral palsy) * (5) had a developmental deficit (e.g., Down's syndrome and other chromosomal disorders) * (6) have suffered from psychiatric diseases or used antipsychotic drugs * (7) had peripheral neuropathy symptoms caused by diabetes, genetic diseases, spinal cord injury, or alcoholism, or * (8) had other neuromuscular disorders (e.g., traumatic brain injury, cerebral palsy).
References
Publications (0)
Data not yet available